Abstract 292P
Background
Shared decision making (SDM) is a dynamic clinical process where physicians and patients mutually and actively share information and collaborate to discuss available evidence during treatment decisions, and where patients are supported to consider options in order to achieve informed preferences. It has become a hallmark of patient-centered care and communication which highlights physician-patient relationship as the core in improving health outcomes, and refers to the type of care that is responsive to the individual needs and preferences of the patient, ensuring that clinical decisions are aligned with his or her values. In cancer care, preference-sensitive decisions range from screening decisions, to treatment decisions, and to end-of-life care. There is little experience with SDM in the Philippines and its integration into the practice of Oncology. The objective of this study was to explore patient perception and evaluate the extent to which a shared decision-making process is implemented in clinical encounters at the Cancer Institute adult outpatient clinics of the Philippine General Hospital.
Methods
The SDM Q-9 Filipino version was administered to 267 patients who were consulting at the adult outpatient clinics of the Cancer Institute over one month.
Results
More than 90% of the patients surveyed agreed that shared decision-making process were being practiced at the Cancer Institute adult outpatient clinics. Of these, almost half of the respondents answered “somewhat agreed” in all items, except for the domain which sought if the physician helped the patient to understand information which showed stronger trend towards agreement. Notably, the domains involving identification of preferences and shared decision showed weaker trend towards agreement, with 5% and 7% of patients surveyed disagreeing that these steps were being observed in practice, respectively. This indicated that among the nine items of the SDM Q-9, these areas required the most strengthening.
Conclusions
In this study, the investigators observed that cancer patients agreed that shared decision making was being practiced during their clinical encounters with their respective physicians.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
193P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Exploratory survival analyses by change in post treatment CA 19-9
Presenter: Andrew Dean
Session: e-Poster Display Session
194P - Nab-paclitaxel plus capecitabine as first-line treatment for patients with recurrence or metastatic biliary tract cancer
Presenter: Jun Zhou
Session: e-Poster Display Session
370P - Bespoke circulating tumour DNA assay for the detection of minimal residual disease in esophageal adenocarcinoma patients
Presenter: Emma Ococks
Session: e-Poster Display Session
390P - A real-world clinical study of camrelizumab in the treatment of esophageal cancer
Presenter: Guoping Sun
Session: e-Poster Display Session
203P - Characterization of renal cell carcinoma (RCC) with VHL mutation
Presenter: Yanrui Zhang
Session: e-Poster Display Session
204P - Prospective observational study on pazopanib in patients treated for advanced or metastatic renal cell carcinoma (RCC) in Asia, North Africa and Middle East countries: Final analysis of PARACHUTE study
Presenter: Ravindran Kanesvaran
Session: e-Poster Display Session
205P - A study on organ preservation in muscle invasive urinary bladder cancer patients with intensity modulated radiotherapy and concurrent single agent cisplatin in south Indian population
Presenter: Himani Manchala
Session: e-Poster Display Session
206P - Mutational signature in urothelial carcinoma with TP53 mutation
Presenter: Huan Liu
Session: e-Poster Display Session
207P - Concordance of genomic alterations by next-generation sequencing in tumour tissue versus circulating tumour DNA in urothelial carcinoma
Presenter: wang Wang
Session: e-Poster Display Session
208P - Prognostic factors and outcomes of non-seminomatous germ cell tumours of testis: Experience from a tertiary cancer centre in India
Presenter: Lekha Nair
Session: e-Poster Display Session